Ann: Neurotech Investor Presentation, page-94

From your waffle, then I can at least gather one useful thing... that it's for no more than 15% of capital.

So circa $3m, or 3 further quarters of research and expenses, in addition to the $1.2m that will remain in cash on balance sheet as of this date.

Placement at 20c of $3m will cause minimal dilution, and as I've said before is completely necessary.

So we have 1 year from this date to start seeing significant sales being made. That looks like it will be enough time for FDA, sales ramp in Germany, Austria, Italy, Greece, Australia, distribution agreements in U.K. and hopefully US.

Finally Tadpole, you've started commenting on this Stock with regularity around 3 weeks ago at the time of the first TH, I have been posting regularly for over one year, the same amount of time as holding >1% shareholding of the company. Please remember that.